1. Brain metastases free survival differs between breast cancer subtypes
- Author
-
H. Eiter, Peter Dubsky, Günther G. Steger, Zsuzsanna Bago-Horvath, Matthias Preusser, Christoph C. Zielinski, Ursula Pluschnig, Florian Fitzal, C De Vries, Michael Knauer, Andrea Rottenfusser, Rupert Bartsch, Margaretha Rudas, Karin Dieckmann, Robert M. Mader, Anna S. Berghoff, and Michael Gnant
- Subjects
Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Pathology ,Lung Neoplasms ,Receptor, ErbB-2 ,Breast Neoplasms ,In situ hybridization ,Disease-Free Survival ,Breast cancer ,carcinomatous meningitis ,Internal medicine ,brain metastases ,Clinical Studies ,human epidermal growth factor receptor 2 (HER-2)-positive breast cancer ,medicine ,Biomarkers, Tumor ,Humans ,Survival analysis ,In Situ Hybridization, Fluorescence ,Aged ,Neoplasm Staging ,Retrospective Studies ,advanced breast cancer ,Aged, 80 and over ,Lung ,business.industry ,Brain Neoplasms ,Incidence (epidemiology) ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Metastatic breast cancer ,Immunohistochemistry ,medicine.anatomical_structure ,Receptors, Estrogen ,Austria ,Female ,triple-negative disease ,business ,Receptors, Progesterone - Abstract
Background: Brain metastases (BM) are frequently diagnosed in patients with HER-2-positive metastatic breast cancer; in addition, an increasing incidence was reported for triple-negative tumours. We aimed to compare brain metastases free survival (BMFS) of breast cancer subtypes in patients treated between 1996 until 2010. Methods: Brain metastases free survival was measured as the interval from diagnosis of extracranial breast cancer metastases until diagnosis of BM. HER-2 status was analysed by immunohistochemistry and reanalysed by fluorescent in situ hybridisation if a score of 2+ was gained. Oestrogen-receptor (ER) and progesterone-receptor (PgR) status was analysed by immunohistochemistry. Brain metastases free survival curves were estimated with the Kaplan–Meier method and compared with the log-rank test. Results: Data of 213 patients (46 luminal/124 HER-2/43 triple-negative subtype) with BM from breast cancer were available for the analysis. Brain metastases free survival differed significantly between breast cancer subtypes. Median BMFS in triple-negative tumours was 14 months (95% CI: 11.34–16.66) compared with 18 months (95% CI: 14.46–21.54) in HER-2-positive tumours (P=0.001) and 34 months (95% CI: 23.71–44.29) in luminal tumours (P=0.001), respectively. In HER-2-positive patients, co-positivity for ER and HER-2 prolonged BMFS (26 vs 15 m; P=0.033); in luminal tumours, co-expression of ER and PgR was not significantly associated with BMFS. Brain metastases free survival in patients with lung metastases was significantly shorter (17 vs 21 months; P=0.014). Conclusion: Brain metastases free survival in triple-negative breast cancer, as well as in HER-2-positive/ER-negative, is significantly shorter compared with HER-2/ER co-positive or luminal tumours, mirroring the aggressiveness of these breast cancer subtypes.
- Published
- 2012